Michele Pezzella

Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells

Michele Pezzella, Concetta Quintarelli, Maria Cecilia Quadraccia, Andrea Sarcinelli et autres

Sarcomas are rare, mesenchymal tumors, representing about 10–15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid tumors. In this preclinical study, we investigated the potential use of …

it, jp (code pays fourni par la source)

Supplemental Figure 12 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 12. DAOY-GFP tumor bearing-mice treated with Tazemetostat to evaluate GD2 upregulation in vivo.

Supplemental Figure 5 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 5. Real-Time killing assay of CAR.GD2 T-cells vs DAOY-GFP cell line.

Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

AbstractPurpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated …

Supplemental Figure 6 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 6. CAR.GD2 T-cells spare the elimination of MB cells with a dim expression of GD2.

Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells.

Supplemental Video 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Video 2. IncuCyte® live-cell System video of Cytotoxic activity of NT or CAR.GD2 T-cells vs DAOY-GFP-FF-Luc cell line. The video shows 84 hours of tumor growth (DAOY cell line) with only tumor (A) and with tumor cells co-cultured with NT T-cells …

Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 8. Tazemetostat did not modulate GD2 expression in normal cells.

Supplemental Figure 17 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 17. Evaluation of the NT T-cell infiltration in MB xenograft mouse model.

Supplemental Video 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Video 2. IncuCyte® live-cell System video of Cytotoxic activity of NT or CAR.GD2 T-cells vs DAOY-GFP-FF-Luc cell line. The video shows 84 hours of tumor growth (DAOY cell line) with only tumor (A) and with tumor cells co-cultured with NT T-cells …

Supplemental Figure 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 2. GD2 evaluation in MB cell lines.

Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella et autres

Supplemental Figure 16. Evaluation of the efficacy of AP1903 CAR.GD2 T-cells infiltrating tumor in in vivo MB xenograft mouse model.